Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with -$87.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 22.94% to -$87.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$311.4 million, a 39.08% decrease, with the full-year FY2025 number at -$311.4 million, down 39.08% from a year prior.
  • Net Income towards Common Stockholders was -$87.0 million for Q4 2025 at Kymera Therapeutics, down from -$82.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$13.1 million in Q1 2021 to a low of -$87.0 million in Q4 2025.
  • A 5-year average of -$48.6 million and a median of -$42.5 million in 2022 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 58.79% in 2023, then crashed 392.43% in 2024.
  • Kymera Therapeutics' Net Income towards Common Stockholders stood at -$24.7 million in 2021, then crashed by 41.38% to -$34.9 million in 2022, then soared by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then fell by 22.94% to -$87.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Net Income towards Common Stockholders are -$87.0 million (Q4 2025), -$82.2 million (Q3 2025), and -$76.6 million (Q2 2025).